At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 6, 2019, among other things, the following was resolved: About Infant Bacterial...
Message from the CEO As previously communicated, IBT had a meeting with the Food and Drug Administration (FDA) on November 20, 2018, to discuss IBT’s...
Infant Bacterial Therapeutics AB has today signed the first distribution agreement for IBP-9414 with Megapharm Ltd. for the Israeli market and the Palestinian...
Message from the CEO IBT reached several significant milestones during 2018. IBT reached agreement with a CRO (Contract Research Organization) to conduct...
The Phase III study protocol is modified after IBT’s meeting with the FDA Yesterday afternoon (EST) Infant Bacterial Therapeutics had a meeting with...
The Annual General Meeting of 2018 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the...